Medi-Ject Corp. announced Friday that it has entered into anagreement with Cangene Corp. of Toronto to package anddeliver certain of Cangene's biopharmaceuticals, using aneedle-less personal administration device being developed byMedi-Ject.
Medi-Ject of Minneapolis said it believes that the devices,which will be based on the company's Medi-Jector insulin-administration system, will strongly compete with conventionalneedles and syringes for home use.
Cangene is a biotechnology company primarily focused onblood cell growth factors.
(c) 1997 American Health Consultants. All rights reserved.